ANAB

Dennis Mulroy

Known title: Chief Financial OfficerCIK: 0001276840

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 13, 2026

AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.

this person other insiders at ANAB

Transaction History

ANAB▼ Sell$112K
ANAB▲ Buy—
ANAB▼ Sell$86K
ANAB▲ Buy—
ANAB▼ Sell$145K
ANAB▲ Buy—
ANAB▲ Buy$202K
ANAB▼ Sell$500K
ANAB▲ Buy$202K
ANAB▼ Sell$418K
ANAB▼ Sell$288K
ANAB▲ Buy—
ANAB▼ Sell$31K
ANAB▲ Buy—
ANAB▼ Sell$50K
ANAB▼ Sell$86K
ANAB▲ Buy$202K
ANAB▼ Sell$401K
ANAB▲ Buy—
ANAB▼ Sell$36K
ANAB▼ Sell$72K
ANAB▼ Sell$48K
ANAB▲ Buy$0
ANAB▼ Sell$75K
ANAB▲ Buy—
ANAB▼ Sell$41K
ANAB▲ Buy$21K

We use analytics to understand how market-wall is used. No personal data is sold.